TurboHawk斑块切除系统在下肢动脉粥样硬化闭塞症中的应用

Application of TurboHawk plaque resection system in the treatment of lower extremity arteriosclerosis obliterans

目的评价TurboHawk斑块切除系统在下肢动脉粥样硬化闭塞症治疗中的疗效和安全性。方法回顾性分析2016年1月-2017年8月解放军福州总医院使用TurboHawk斑块切除系统治疗的36例下肢动脉粥样硬化闭塞症患者的临床资料，分析其病变特点、症状改善情况、术前和术后踝肱指数（ABI）、术后并发症情况。所有患者术后每3个月于门诊复查，随访3～18个月，平均（9±0．5）个月。计量资料以均数±标准差（x±s）表示，治疗前后ABI比较采用配对t检验；计数资料以率（％）表示，不同分期比较采用，检验。结果36例下肢动脉粥样硬化闭塞症患者病变段均获得再通，技术成功率为100％，下肢症状获得明显改善。术后3dABI（0．85±0．07）及术后3个月ABI（0．75±0．10）均较术前（0．29±0．10）明显好转（t=37．76，P〈0．001）。术后出现并发症2例，其中1例出现夹层，使用裸支架覆盖；另1例旋切后出现血管破裂，使用球囊压迫成形，破口封闭。结论TurboHawk斑块切除系统在下肢动脉粥样硬化闭塞症的治疗中近期疗效确切，创伤小，安全性高，可作为此类疾病治疗的一种选择。

Objective To evaluate the efficacy and safety of TurboHawk plaque resection system in the treatment of lower extremity arteriosclerosis obliterans.Methods Clinical data of 36 patients with atherosclerotic occlusion of lower extremity treated with TurboHawk from January 2016 to August 2017 were retrospectively collected.The characteristics of lesion,improvement of symptoms,ankle brachial index （ABI） and postoperative complications were analyzed.The measurement data were expressed as （（x） ± s）,All patients were reviewed every 3 months after operation,followed up for 3-18 months,with an average of （9 ± 0.5） months.And the ABI comparison before and after treatment were performed by paired t test;the counting data were expressed as rate （%）,and the comparison of different stages was performed by chi-square test.Results In 36 patients,the technical success rate was 100%,and the symptoms of lower limbs were significantly improved.The ABI （0.85 ±0.07） and ABI （0.75 ±0.10） were significantly better in 3 days and in 3 months after operation than before operation （0.29 ±0.10）（t =37.76,P 〈0.001）.Postoperative complications occurred in 2 cases,in one case,the artery dissection was covered with a bare scaffold,and in the other case,the blood vessel was ruptured after resection,and was closured by using balloon angioplasty.Conclusion TurboHawk plaque resection system is an effective,less traumatic and safer option for the treatment of lower extremity arteriosclerosis obliterans.